Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

How I treat… alcohol-related liver disease.

Tyson LD, Lewis H.

Clin Med (Lond). 2019 Jan;19(1):43-46. doi: 10.7861/clinmedicine.19-1-43. Review.

2.

Charged hydrophilic polymer brushes and their relevance for understanding marine biofouling.

Yandi W, Mieszkin S, di Fino A, Martin-Tanchereau P, Callow ME, Callow JA, Tyson L, Clare AS, Ederth T.

Biofouling. 2016 Jul;32(6):609-25. doi: 10.1080/08927014.2016.1170816.

3.

Hydration and chain entanglement determines the optimum thickness of poly(HEMA-co-PEG₁₀MA) brushes for effective resistance to settlement and adhesion of marine fouling organisms.

Yandi W, Mieszkin S, Martin-Tanchereau P, Callow ME, Callow JA, Tyson L, Liedberg B, Ederth T.

ACS Appl Mater Interfaces. 2014 Jul 23;6(14):11448-58. doi: 10.1021/am502084x. Epub 2014 Jul 1.

4.

Harnessing technology to improve clinical trials: study of real-time informatics to collect data, toxicities, image response assessments, and patient-reported outcomes in a phase II clinical trial.

Pietanza MC, Basch EM, Lash A, Schwartz LH, Ginsberg MS, Zhao B, Shouery M, Shaw M, Rogak LJ, Wilson M, Gabow A, Latif M, Lin KH, Wu Q, Kass SL, Miller CP, Tyson L, Sumner DK, Berkowitz-Hergianto A, Sima CS, Kris MG.

J Clin Oncol. 2013 Jun 1;31(16):2004-9. doi: 10.1200/JCO.2012.45.8117. Epub 2013 Apr 29.

5.

Collect, boil and amplify--a simple approach for the detection of three common viruses associated with epidemic keratoconjunctivitis, conjunctivitis and dendritic ulcers.

Moore C, Gatica L, Jones T, Matthews P, Watkins J, Tyson L, Keelan P, Corden S, Phillips I, Jones R.

J Virol Methods. 2013 Apr;189(1):238-41. doi: 10.1016/j.jviromet.2013.01.021. Epub 2013 Feb 11.

PMID:
23411346
6.

StemCellDB: the human pluripotent stem cell database at the National Institutes of Health.

Mallon BS, Chenoweth JG, Johnson KR, Hamilton RS, Tesar PJ, Yavatkar AS, Tyson LJ, Park K, Chen KG, Fann YC, McKay RD.

Stem Cell Res. 2013 Jan;10(1):57-66. doi: 10.1016/j.scr.2012.09.002. Epub 2012 Sep 26.

7.

Accurately administering oral medication to children isn't child's play.

Beckett VL, Tyson LD, Carroll D, Gooding NM, Kelsall AW.

Arch Dis Child. 2012 Sep;97(9):838-41. doi: 10.1136/archdischild-2012-301850.

PMID:
22936212
8.

How has genetic testing changed treatment approaches for patients with lung cancer?

Tyson LB.

ONS Connect. 2012 Feb;27(2):15. No abstract available.

PMID:
22375507
9.

Use of a Drosophila genome-wide conserved sequence database to identify functionally related cis-regulatory enhancers.

Brody T, Yavatkar AS, Kuzin A, Kundu M, Tyson LJ, Ross J, Lin TY, Lee CH, Awasaki T, Lee T, Odenwald WF.

Dev Dyn. 2012 Jan;241(1):169-89. doi: 10.1002/dvdy.22728. Epub 2011 Aug 30.

10.

Pralatrexate with vitamin supplementation in patients with previously treated, advanced non-small cell lung cancer: safety and efficacy in a phase 1 trial.

Azzoli CG, Patel JD, Krug LM, Miller V, James L, Kris MG, Ginsberg M, Subzwari S, Tyson L, Dunne M, May J, Huntington M, Saunders M, Sirotnak FM.

J Thorac Oncol. 2011 Nov;6(11):1915-22. doi: 10.1097/JTO.0b013e31822adb19.

11.

A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer.

Paik PK, Rudin CM, Pietanza MC, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM.

Lung Cancer. 2011 Dec;74(3):481-5. doi: 10.1016/j.lungcan.2011.05.005. Epub 2011 May 26.

12.

Neural crest origin of olfactory ensheathing glia.

Barraud P, Seferiadis AA, Tyson LD, Zwart MF, Szabo-Rogers HL, Ruhrberg C, Liu KJ, Baker CV.

Proc Natl Acad Sci U S A. 2010 Dec 7;107(49):21040-5. doi: 10.1073/pnas.1012248107. Epub 2010 Nov 15.

13.

WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer.

Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, Korontsvit T, Zakhaleva V, Wolchok J, Yuan J, Li H, Tyson L, Scheinberg DA.

Cancer Immunol Immunother. 2010 Oct;59(10):1467-79. doi: 10.1007/s00262-010-0871-8. Epub 2010 Jun 8.

14.

A phase I study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in solid tumor malignancies.

Paik PK, Rudin CM, Brown A, Rizvi NA, Takebe N, Travis W, James L, Ginsberg MS, Juergens R, Markus S, Tyson L, Subzwari S, Kris MG, Krug LM.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1079-85. doi: 10.1007/s00280-010-1265-5. Epub 2010 Feb 18.

15.

An economic assessment of patent settlements in the pharmaceutical industry.

Dickey B, Orszag J, Tyson L.

Ann Health Law. 2010 Winter;19(2):367-400, 2 p preceding i.

PMID:
21443148
16.

Putting evidence into practice: evidence-based interventions for cancer-related dyspnea.

DiSalvo WM, Joyce MM, Tyson LB, Culkin AE, Mackay K.

Clin J Oncol Nurs. 2008 Apr;12(2):341-52. doi: 10.1188/08.CJON.341-352. Review.

17.

Introduction.

Houlihan NG, Tyson LB.

Semin Oncol Nurs. 2008 Feb;24(1):1-2. doi: 10.1016/j.soncn.2007.11.006. No abstract available.

PMID:
18222145
18.

Non-small cell lung cancer: new hope for a chronic illness.

Tyson LB.

Oncol Nurs Forum. 2007 Sep;34(5):963-70. Review. No abstract available.

PMID:
17878125
19.

Prospective assessment of discontinuation and reinitiation of erlotinib or gefitinib in patients with acquired resistance to erlotinib or gefitinib followed by the addition of everolimus.

Riely GJ, Kris MG, Zhao B, Akhurst T, Milton DT, Moore E, Tyson L, Pao W, Rizvi NA, Schwartz LH, Miller VA.

Clin Cancer Res. 2007 Sep 1;13(17):5150-5.

20.

A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer.

Azzoli CG, Krug LM, Miller VA, Rizvi NA, Kris MG, Dunne M, Farmer A, Pizzo B, Tyson L, Seeger T, Coleman B, Moore E, Lastinger L, Venkatraman E, Rudin CM.

J Thorac Oncol. 2007 Jul;2(7):638-44.

21.

A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors.

Azzoli CG, Krug LM, Gomez J, Miller VA, Kris MG, Ginsberg MS, Henry R, Jones J, Tyson L, Dunne M, Pizzo B, Farmer A, Venkatraman E, Steffen R, Sirotnak FM.

Clin Cancer Res. 2007 May 1;13(9):2692-8.

22.

Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.

Krug LM, Miller VA, Patel J, Crapanzano J, Azzoli CG, Gomez J, Kris MG, Heelan RT, Pizzo B, Tyson L, Sheehan C, Ross JS, Venkatraman E.

Cancer. 2005 Nov 15;104(10):2149-55.

23.

Imatinib mesylate lacks activity in small cell lung carcinoma expressing c-kit protein: a phase II clinical trial.

Krug LM, Crapanzano JP, Azzoli CG, Miller VA, Rizvi N, Gomez J, Kris MG, Pizzo B, Tyson L, Dunne M, Heelan RT.

Cancer. 2005 May 15;103(10):2128-31.

24.

Practical management of patients with non-small-cell lung cancer treated with gefitinib.

Shah NT, Kris MG, Pao W, Tyson LB, Pizzo BM, Heinemann MH, Ben-Porat L, Sachs DL, Heelan RT, Miller VA.

J Clin Oncol. 2005 Jan 1;23(1):165-74. Epub 2004 Nov 22.

PMID:
15557594
25.

Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Hood C, Kris MG, Miller VA, Allen JR, Keding SJ, Danishefsky SJ, Gomez J, Tyson L, Pizzo B, Baez V, Livingston PO.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6094-100.

26.

Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer.

Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, Krug LM, Pao W, Rizvi N, Pizzo B, Tyson L, Venkatraman E, Ben-Porat L, Memoli N, Zakowski M, Rusch V, Heelan RT.

J Clin Oncol. 2004 Mar 15;22(6):1103-9.

PMID:
15020612
27.

Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.

Krug LM, Ragupathi G, Ng KK, Hood C, Jennings HJ, Guo Z, Kris MG, Miller V, Pizzo B, Tyson L, Baez V, Livingston PO.

Clin Cancer Res. 2004 Feb 1;10(3):916-23.

28.

10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.

Krug LM, Azzoli CG, Kris MG, Miller VA, Khokhar NZ, Tong W, Ginsberg MS, Venkatraman E, Tyson L, Pizzo B, Baez V, Ng KK, Sirotnak FM.

Clin Cancer Res. 2003 Jun;9(6):2072-8.

29.

Nursing assessment and management of dyspneic patients with lung cancer.

Inzeo D, Tyson L.

Clin J Oncol Nurs. 2003 May-Jun;7(3):332-3. Review.

PMID:
12793341
30.

Pilot trial of the epidermal growth factor receptor tyrosine kinase inhibitor gefitinib plus carboplatin and paclitaxel in patients with stage IIIB or IV non-small-cell lung cancer.

Miller VA, Johnson DH, Krug LM, Pizzo B, Tyson L, Perez W, Krozely P, Sandler A, Carbone D, Heelan RT, Kris MG, Smith R, Ochs J.

J Clin Oncol. 2003 Jun 1;21(11):2094-100.

PMID:
12775734
31.

Biomechanical evaluation of lateral patellar dislocations.

Burks RT, Desio SM, Bachus KN, Tyson L, Springer K.

Am J Knee Surg. 1998 Winter;11(1):24-31.

PMID:
9533050
32.

Drugs and violence among Ontario students.

Smart RG, Mann RE, Tyson LA.

J Psychoactive Drugs. 1997 Oct-Dec;29(4):369-73.

PMID:
9460031
33.

Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin.

Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD.

Cancer. 1996 Nov 15;78(10):2193-8.

PMID:
8918414
34.

High-dose edatrexate with oral leucovorin rescue: a phase I and clinical pharmacological study in adults with advanced cancer.

Pisters KM, Tyson LB, Tong W, Fleisher M, Miller VA, Grant SC, Pfister DG, Rigas JR, Densmore CL, Krol G, Heelan RT, Sirotnak FM, Bertino JR, Kris MG.

Clin Cancer Res. 1996 Nov;2(11):1819-24.

35.

Oral combination antiemetics in patients with small cell lung cancer receiving cisplatin or cyclophosphamide plus doxorubicin.

Cleri LB, Kris MG, Tyson LB, Pisters KM, Clark RA, Gralla RJ.

Cancer. 1995 Sep 1;76(5):774-8.

PMID:
8625179
36.

MRI appearance of meniscal cysts.

Tyson LL, Daughters TC Jr, Ryu RK, Crues JV 3rd.

Skeletal Radiol. 1995 Aug;24(6):421-4.

PMID:
7481898
37.

Imaging of the painful shoulder.

Tyson LL.

Curr Probl Diagn Radiol. 1995 May-Jun;24(3):110-40. Review.

PMID:
7614836
38.
39.

Dose-ranging evaluation of the serotonin antagonist dolasetron mesylate in patients receiving high-dose cisplatin.

Kris MG, Grunberg SM, Gralla RJ, Baltzer L, Zaretsky SA, Lifsey D, Tyson LB, Schmidt L, Hahne WF.

J Clin Oncol. 1994 May;12(5):1045-9.

PMID:
8164028
41.

Enhancing the effectiveness of the specific serotonin antagonists. Combination antiemetic therapy with dexamethasone.

Kris MG, Baltzer L, Pisters KM, Tyson LB.

Cancer. 1993 Dec 1;72(11 Suppl):3436-42. Review.

PMID:
8242576
42.

Dose-ranging antiemetic evaluation of the serotonin antagonist RG 12915 in patients receiving anticancer chemotherapy.

Baltzer L, Kris MG, Tyson LB, Rigas JR, Vreeland F, Pisters KM.

Cancer. 1993 Nov 1;72(9):2695-9.

PMID:
8402492
43.

Midazolam in patients receiving anticancer chemotherapy and antiemetics.

Potanovich LM, Pisters KM, Kris MG, Tyson LB, Clark RA, Baltzer L, Gralla RJ.

J Pain Symptom Manage. 1993 Nov;8(8):519-24.

44.

Pathogenesis of rotator cuff disorders. Magnetic resonance imaging characteristics.

Tyson LL, Crues JV 3rd.

Magn Reson Imaging Clin N Am. 1993 Sep;1(1):37-46. Review.

PMID:
7584213
45.

Phase II trial of a single intravenous dose of ondansetron in patients receiving cisplatin > or = 100 mg/m2.

Kris MG, Clark RA, Tyson LB, Hahne WF, Pisters KM, Gralla RJ.

Am J Clin Oncol. 1993 Feb;16(1):77-80.

PMID:
8424410
46.

Dose-ranging evaluation of the substituted benzamide dazopride when used as an antiemetic in patients receiving anticancer chemotherapy.

Grant SC, Kris MG, Gralla RJ, Clark RA, Tyson LB.

Cancer Chemother Pharmacol. 1993;31(6):442-4.

PMID:
8453682
47.

Tropisetron (ICS 205-930): a selective 5-hydroxytryptamine antagonist.

Kris MG, Tyson LB.

Eur J Cancer. 1993;29A Suppl 1:S30-2. Review. No abstract available.

PMID:
8427722
48.

Dose-ranging antiemetic evaluation of the serotonin antagonist tropisetron in patients receiving anti-cancer chemotherapy.

Pisters KM, Kris MG, Tyson LB, Clark RA, Gralla RJ.

Cancer. 1993 Jan 1;71(1):226-30.

PMID:
8416720
49.
50.

Dose-ranging trial of zacopride: the emetic antiemetic?

Pisters KM, Kris MG, Tyson LB, Clark RA, Gralla RJ.

J Natl Cancer Inst. 1992 May 6;84(9):717-8. No abstract available.

PMID:
1569606

Supplemental Content

Support Center